

For Public Release


NZX Limited
Wellington

23 January 2024

Cannasouth Trading Update

Cannasouth Limited (NZX:CBD), New Zealand's first and largest listed medicinal cannabis company, is pleased to provide this trading update as the Group commences sales of its own-manufactured CBD oral solutions and dried cannabis flower products.

Group Revenues



Commercial sales of these products commenced in November 2023 following a lengthy verified process by the Medicinal Cannabis Agency. We are confident with the launch of our new products and expect ongoing revenue growth as clinics and prescribers obtain access to our product range either direct, or via wholesalers.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO / Executive Director
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Colin Foster

CFO / Company Secretary
Email: colin.foster@cannasouth.co.nz
Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Equis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>